Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects.
糖尿病藥物中的胰高血糖素樣肽-1受體激動劑和鈉-葡萄糖共轉運蛋白2抑制劑對心臟衰竭和認知障礙的保護作用:潛在的保護效應機制。
Front Pharmacol 2024-07-01
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.
心衰中的心臟代謝藥物二型鈉葡萄糖轉運蛋白抑製劑和葡萄糖樣肽-1 受體激動劑的保護效應潛在機制。
Int J Mol Sci 2024-03-15
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system.
SGLT2 抑制劑:通過對神經系統的多方面影響治療認知障礙的新療法。
Transl Neurodegener 2024-08-09
Unveiling the Potential Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Offering Protection of the Cardiovascular, Renal, and Neural Systems: An Updated Narrative Review.
揭示胰高血糖素樣肽-1 (GLP-1) 受體激動劑在保護心血管、腎臟和神經系統中的潛在作用:更新的敘述性綜述。
Cureus 2024-09-02
Neuroprotective Effects of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors (Gliflozins) on Diabetes-Induced Neurodegeneration and Neurotoxicity: A Graphical Review.
鈉-葡萄糖共轉運蛋白-2 (SGLT2) 抑制劑 (Gliflozins) 對糖尿病引起的神經退行性變和神經毒性的神經保護作用:圖形回顧。
Int J Prev Med 2024-09-06
The Promising Potency of Sodium-Glucose Cotransporter 2 Inhibitors in the Prevention of and as Treatment for Cognitive Impairment Among Type 2 Diabetes Patients.
鈉-葡萄糖共轉運蛋白 2 抑制劑在預防及治療 2 型糖尿病患者認知障礙中的潛在效能。
Biomedicines 2025-01-08